# Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

> **NCT06449313** · PHASE2 · RECRUITING · sponsor: **Georgetown University** · enrollment: 21 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** Cemiplimab-Rwlc

## Key facts

- **NCT ID:** NCT06449313
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12
- **Final completion:** 2032-09
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449313, "Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06449313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*